Human Microbiome Market by Disease, Technology, Product, Therapeutic Area, Application

List of Tables

[198 Pages Report] The Human Microbiome Market size was estimated at USD 1.58 billion in 2023 and expected to reach USD 1.96 billion in 2024, at a CAGR 23.90% to reach USD 7.11 billion by 2030.

The human microbiome is the collective genomes of the microorganisms that reside on and inside the human body. These include bacteria, archaea, viruses, and eukaryotic microbes. The human body hosts trillions of these microbial cells, which can influence bodily functions and health. It assists in the digestion of food, protection against pathogens, and the development of the immune system. Meanwhile, the rise in chronic disease prevalence and a growing need for research linking the microbiome to various health conditions further stokes demand for microbiome-based diagnostics and therapeutics. The growing need for a microbiome in nutrition propels the demand for a human microbiome to support and influence overall wellness and immune function. However, the regulatory hurdles associated with approving live biotherapeutic products and complexities in comprehending and manipulating the microbiome present a significant challenge for the key players. Companies are continuously focusing on research and development (R&D) activities and cost-effective and accessible sequencing technologies to optimize their business growth. Moreover, the advancements in developing novel human microbiome therapeutics and rising investments present a significant opportunity for the key companies operating in the global space. Emerging technologies such as artificial intelligence (AI) and advanced machine learning (ML) are integrated with microbiome research to understand complex microbial interactions better and develop novel therapeutic solutions.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.58 billion
Estimated Year [2024]	USD 1.96 billion
Forecast Year [2030]	USD 7.11 billion
CAGR (%)	23.90%

Technology: Recent advancements in 16s rRNA sequencing and omics technology to investigate molecular factors and processes in human body

16s ribosomal RNA sequencing is a widely used method for identifying and comparing bacteria within a sample. It focuses on the 16S rRNA gene, a component of the 30S small subunit of prokaryotic ribosomes, which is highly conserved within different species of bacteria and archaea. This technique helps researchers classify and determine the phylogeny of bacteria, providing insights into the microbiome's composition. On the other hand, cell culture technology involves growing cells under controlled conditions, typically outside their natural environment. In microbiome research, cell culture technology allows scientists to isolate and maintain microorganisms for study. High-throughput technologies, including next-generation sequencing (NGS), have revolutionized the speed and scale at which microbial communities can be studied. These methods allow for the simultaneous sequencing of millions of DNA molecules, offering a comprehensive view of the microbiome's diversity and function. Moreover, metagenomic sequencing analyzes the genetic material obtained from environmental samples, helping researchers bypass the need to cultivate organisms in the lab. This technology helps study the human microbiome by allowing for a culture-independent examination of the genetic material of all microorganisms present, including those not easily cultured in vitro. Furthermore, omics technologies, such as genomics, transcriptomics, proteomics, and metabolomics, provide holistic views and high-resolution insights into biological systems. In microbiome research, these technologies investigate various molecular factors and processes, such as the genomics RNA transcripts, proteomics, and metabolites of microbial communities.

Application: The increasing adoption of the human microbiome in healthcare diagnostics and therapeutics to cater to various health conditions

The human microbiome, comprised of the collective genome of microorganisms residing in and on the human body, has become an area of increasing interest for its potential in diagnostics. Advancements in next-generation sequencing and bioinformatics have allowed researchers to correlate specific microbial compositions and activities with various health conditions. For diagnostics, analysis of the human microbiome facilitates the identification of biomarkers for diseases such as inflammatory bowel disease, diabetes, and certain types of cancer. In the therapeutic domain, the human microbiome offers the potential for personalized medicine through microbiota-based treatments. Fecal microbiota transplantation (FMT) is used to treat clostridium difficile infections by restoring a healthy microbial balance.

Regional Insights

In the Americas, the United States and Canada witnessed significant growth in human microbiome driven by the research and commercialization of advanced microbiome, with numerous companies actively engaged in developing microbiome-based therapies and diagnostics. The human microbiome landscape in this region is steadily growing, focusing on research aimed at understanding the impact of the microbiome on human health and disease. On the other hand, European countries exhibit strong government support for microbiome research with numerous initiatives and research consortia in place. The regulatory framework in Europe is evolving to support the safe and ethical use of microbiome data and products. The Middle East and Africa region represents a growing market for human microbiome products, primarily driven by an increasing burden of lifestyle diseases and growing healthcare expenditure. At the same time, the human microbiome landscape in the Asia-Pacific region is experiencing significant growth, driven by increasing awareness of the importance of microbial balance to overall health, rising healthcare expenditures, and advancements in microbial genomics. Research and development in probiotics, prebiotics, and symbiotics are growing in this region, particularly in addressing regional health issues such as gastrointestinal disorders and chronic diseases.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Human Microbiome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Microbiome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Human Microbiome Market, highlighting leading vendors and their innovative profiles. These include AOBiome, LLC, Astarte Medical Partners, Inc, Axial Therapeutics, Inc., Azitra, BiomeSense, Inc., BiomX Ltd., DuPont de Nemours, Inc., Enterome Bioscience, Evelo Biosciences, Inc., Exeliom Biosciences SAS, Ferring B.V., Finch Therapeutics Group, Inc., Illumina, Inc., Intralytix, Inc., Invivo Healthcare, Locus Biosciences, Inc., Merck KGaA, Metabiomics Corporation, Osel Inc., Rebiotix Inc., Second Genome, Inc., Seres Therapeutics, Inc., Synlogic, Inc., Theriva Biologics, Inc., Vedanta Biosciences, Inc., Viome Life Sciences, Inc., and Yakult Honsha Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Human Microbiome Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease
- Acute Diarrhea
- Autoimmune Disorders
- Cancer
- Diabetes
- Mental Disorders
- Obesity

Technology
- 16s rRNA Sequencing
- Cell Culture Technology
- Computational Tools
- High-Throughput Technology
- Metagenomic Sequencing
- Omics Technology

Product
- Diagnostic Devices
- Drugs
- Foods
- Prebiotic & Probiotics

Therapeutic Area
- Gastrointestinal Disorders
- Metabolic Disorders
- Skin Disorders
- Women's Health

Application
- Diagnostics
- Therapeutics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Human Microbiome Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Microbiome Market?

3. What are the technology trends and regulatory frameworks in the Human Microbiome Market?

4. What is the market share of the leading vendors in the Human Microbiome Market?

5. Which modes and strategic moves are suitable for entering the Human Microbiome Market?

Product Code: MRR-430D42AA0FCD

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increased Focus on Development of Human Microbiome Therapy
  - 5.1.1.2. Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
  - 5.1.1.3. Increasing Demand for Microbiome in Probiotics and Infant Nutrition
- 5.1.2. Restraints
  - 5.1.2.1. Limited Expertise and Safety Issue related to Microbiome Therapeutics
- 5.1.3. Opportunities
  - 5.1.3.1. Increasing Collaborations and Research Investments to Create Growth Opportunities
  - 5.1.3.2. Development of Novel Human Microbiome Therapeutic Products
- 5.1.4. Challenges
  - 5.1.4.1. Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Recent advancements in 16s rRNA sequencing and omics technology to investigate molecular factors and processes in human body
- 5.2.2. Application: The increasing adoption of the human microbiome in healthcare diagnostics and therapeutics to cater to various health conditions
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization
- 5.9.1. Intellectual Property Landscape

6. Human Microbiome Market, by Disease

6.1. Introduction
6.2. Acute Diarrhea
6.3. Autoimmune Disorders
6.4. Cancer
6.5. Diabetes
6.6. Mental Disorders
6.7. Obesity

7. Human Microbiome Market, by Technology

7.1. Introduction
7.2. 16s rRNA Sequencing
7.3. Cell Culture Technology
7.4. Computational Tools
7.5. High-Throughput Technology
7.6. Metagenomic Sequencing
7.7. Omics Technology

8. Human Microbiome Market, by Product

8.1. Introduction
8.2. Diagnostic Devices
8.3. Drugs
8.4. Foods
8.5. Prebiotic & Probiotics

9. Human Microbiome Market, by Therapeutic Area

9.1. Introduction
9.2. Gastrointestinal Disorders
9.3. Metabolic Disorders
9.4. Skin Disorders
9.5. Women's Health

10. Human Microbiome Market, by Application

10.1. Introduction
10.2. Diagnostics
10.3. Therapeutics

11. Americas Human Microbiome Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Human Microbiome Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Human Microbiome Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Clinical Microbiomics Announces Merger with CosmosID
- 14.3.2. Nestle Partners APC Microbiome on Health and Wellbeing Products
- 14.3.3. UW Medicine Launches a New Center to Study Microbiomes

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio